MNOV - MediciNova, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.73
+0.23 (+2.42%)
As of 2:50PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close9.50
Open9.54
Bid9.70 x 800
Ask9.74 x 800
Day's Range9.52 - 9.74
52 Week Range6.68 - 13.37
Volume43,067
Avg. Volume138,725
Market Cap418.985M
Beta (3Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateJul 24, 2019 - Jul 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research5 days ago

    MNOV: Readying for Phase 3 Trial in Multiple Sclerosis…

    The company is planning to conduct a single Phase 3 trial in patients with secondary progressive MS (SPMS) without relapses with the primary endpoint being the time to 3-month confirmed disability progression as measured by Expanded Disability Status Scale (EDSS). The EDSS is the ‘gold standard’ for assessing disability progression in patients with MS (Kurtzke, 1983).

  • What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)?
    Simply Wall St.5 days ago

    What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)?

    If you want to know who really controls MediciNova, Inc. (NASDAQ:MNOV), then you'll have to look at the makeup of its...

  • GlobeNewswire12 days ago

    MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) following feedback from the FDA (U.S. Food and Drug Administration).

  • GlobeNewswirelast month

    MediciNova to Present at the JMP Securities Life Sciences Conference

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30 am at the St. Regis New York Hotel in New York City. MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through JMP Securities. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market.

  • GlobeNewswire2 months ago

    MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a kick-off meeting for the Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) was held on June 5, 2019 at MediciNova headquarters in La Jolla, California.

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of MediciNova, Inc.

    NEW YORK, May 16, 2019 -- Levi & Korsinsky announces it has commenced an investigation of MediciNova, Inc. (NASDAQ: MNOV) concerning possible breaches of fiduciary duty. To.

  • GlobeNewswire2 months ago

    MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, 2019 at 11:30 am at the Beverly Hilton Hotel in Beverly Hills, California.  MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through B. Riley FBR. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market.

  • Zacks Small Cap Research2 months ago

    MNOV: Plans in Place for Phase 3 Trial in ALS…

    On April 15, 2019, MediciNova, Inc. (MNOV) announced that following review of the protocol the U.S. Food and Drug Administration (FDA) has determined that the company may proceed with the Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). If successful, results from this trial are expected to support a New Drug Application (NDA) for MN-166 in ALS. The Phase 2b/3 clinical trial will be a multi-center, two-arm, randomized, double blind, placebo controlled trial that will compare MN-166 to placebo in 150 patients with ALS.

  • If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today
    Simply Wall St.2 months ago

    If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Buying shares in the best businesses can build meaningful wealth for you and your family. And we...

  • GlobeNewswire3 months ago

    MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its participation at the Kick-off Meeting for the Phase 3 trial, “REgeneration in CErvical DEgenerative Myelopathy (RECEDE Myelopathy)”, a collaboration with University of Cambridge researchers, as well as at the first UK Academic Spine Symposium, which took place on Tuesday, May 7, 2019 at the Royal Society of Medicine in London, UK. Following the events, Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer gave a speech for the official launch of Myelopathy.org hosted by Lord Carter of Coles in the UK Parliament House of Lords on supporting innovative science through its collaboration in the RECEDE Myelopathy Phase 3 trial to evaluate MN-166 (ibudilast) in degenerative cervical myelopathy (DCM) patients.

  • Benzinga3 months ago

    The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...

  • GlobeNewswire3 months ago

    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma. The allowed claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma using MN-166 (ibudilast) as part of a combination therapy.

  • Benzinga3 months ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • GlobeNewswire3 months ago

    MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the protocol and determined that MediciNova may proceed with a Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). If this potentially pivotal trial is successful, the Phase 2b/3 efficacy and safety data is intended to support a New Drug Application (NDA) for MN-166 (ibudilast) in ALS.

  • Zacks Small Cap Research3 months ago

    MNOV: New Analysis Shows Efficacy of MN-166 in Non-Relapsing SPMS…

    The SPRINT-MS trial was a Phase 2b clinical trial of patients with either secondary progressive MS (SPMS) or primary progressive MS (PPMS) in which participants received either MN-166 (100 mg/day) or placebo twice a day for a total of 96 weeks of treatment. The company has previously reported positive results from the SPRINT-MS trial, as it achieved both primary endpoints (a statistically significant 48% reduction in the rate of progression of whole brain atrophy along with safety and tolerability) and also demonstrated effects on important secondary endpoints including a positive trend of a 26% reduction in confirmed disability progression, which would be a primary endpoint in a Phase 3 trial.

  • GlobeNewswire4 months ago

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Chinese Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.  The allowed claims cover the use of MN-001 for reducing a triglyceride blood level, the use of MN-001 for reducing a total cholesterol blood level, and the use of MN-001 for reducing a low density lipoprotein (LDL) blood level.  The allowed claims cover oral administration including liquid and solid dosage forms.

  • GlobeNewswire4 months ago

    MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

    LA JOLLA, Calif., April 01, 2019 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.

  • GlobeNewswire4 months ago

    MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania

    LA JOLLA, Calif., March 24, 2019 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.

  • GlobeNewswire5 months ago

    MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration to evaluate MN-001 (tipelukast) in liver diseases with the Division of Gastroenterology and Hepatology at The Jikei University School of Medicine in Tokyo, Japan. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, “We are very pleased to initiate this collaboration with researchers at The Jikei University evaluating MN-001 in various liver diseases. Multiple animal model studies of MN-001 have demonstrated its anti-fibrotic and anti-inflammatory effects.

  • GlobeNewswire5 months ago

    MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Scientific Reports has published results from the animal model study evaluating MN-166 (ibudilast) in glioblastoma (GBM). The article, “Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF),” is the first publication reporting the potential clinical utility of MN-166 (ibudilast) for GBM.

  • Zacks Small Cap Research5 months ago

    MNOV: Continuing to Plan for Phase 3 Studies in Progressive MS and ALS…

    MediciNova, Inc. (MNOV) is currently developing MN-166 (ibudilast) for a number of indications, with the lead programs being in progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The company has completed Phase 2 clinical trials with positive results from both trial trials. Progressive MS: Previously, the company had reported positive results from the SPRINT-MS Phase 2b clinical trial of MN-166 in patients with progressive MS.

  • One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price
    Simply Wall St.5 months ago

    One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching MediciNova, Inc. (NASDAQ:MNOV) might wantRead More...

  • GlobeNewswire6 months ago

    MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

  • Benzinga6 months ago

    The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 8) Innoviva Inc (NASDAQ: INVA ) Organogenesis Holdings Inc ...

  • GlobeNewswire6 months ago

    MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first glioblastoma patient has enrolled in the clinical trial of MN-166 (ibudilast) in combination with temozolomide (TMZ, Temodar‑®) for the treatment of recurrent glioblastoma (GBM). The principal investigators are Patrick Y. Wen, M.D., Professor of Neurology, Harvard Medical School and Director, Neuro-Oncology Division at the Dana-Farber Cancer Institute (DFCI) in Boston, and Kerrie McDonald, Ph.D., Associate Professor and Head of Biomarkers and Translational Research at the Lowy Cancer Research Centre, University of New South Wales, Australia.